Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

NCT ID: NCT01068912

Last Updated: 2015-11-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

530 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of a 5-day regimen of favipiravir in influenza patients aged 20-80 years. Enrolled patients will be randomly assigned to 1 of 3 parallel treatment dose groups:Placebo; Low-dose favipiravir (1000 mg favipiravir BID for 1 day, followed by 400 mg favipiravir BID for 4 days); High-dose favipiravir (1200 mg favipiravir BID for 1 day, followed by 800 mg favipiravir BID for 4 days).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1: Experimental

Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days

Group Type EXPERIMENTAL

Favipiravir

Intervention Type DRUG

1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days

2: Experimental

High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days

Group Type EXPERIMENTAL

Favipiravir

Intervention Type DRUG

High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo comparator

Intervention Type DRUG

Placebo BID x 1 day, and Placebo BID x 4 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Favipiravir

1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days

Intervention Type DRUG

Favipiravir

High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days

Intervention Type DRUG

Placebo comparator

Placebo BID x 1 day, and Placebo BID x 4 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who test positive for influenza A or B by a commercially available Rapid Antigen Test (RAT) of the nasopharynx. A patient with a negative RAT result may still enroll if the sponsor and investigator agree that there is a known influenza outbreak circulating in the community.
2. Patients ≥ 20 but \< 65 years of age with a temperature (oral) of 100.4°F (38.0°C) or more; patients ≥ 65 years of age with a temperature (oral) of 100.0°F (37.8°C) or more at the first visit, or in the 6 hours prior if antipyretics were taken.
3. Patients with 2 or more of the following symptoms (moderate to severe in intensity) at the time of enrollment:

* Cough
* Sore throat
* Headache
* Nasal congestion
* Feeling feverish
* Body aches and pains
* Fatigue (tiredness)

2. Patients who have underlying chronic respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], chronic bronchitis, diffuse panbronchiolitis, bronchiectasis, pulmonary emphysema, pulmonary fibrosis, bronchial asthma, or old tuberculosis).
3. Patients who at the beginning of the study are suspected of having bacterial respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or infiltrate in lung in a chest x-ray, etc.).
4. Patients who have serious chronic diseases. For example, patients with HIV, cancer (i.e., requiring chemotherapy within the preceding 6 months), cirrhosis (end-stage), and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days.
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MDVI, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Macy Guiont

Role: STUDY_DIRECTOR

Syneos Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

#065

Birmingham, Alabama, United States

Site Status

#156

Huntsville, Alabama, United States

Site Status

#151

Mobile, Alabama, United States

Site Status

#155

Scottsboro, Alabama, United States

Site Status

#173

Toney, Alabama, United States

Site Status

#161

Tuscumbia, Alabama, United States

Site Status

#089

Chandler, Arizona, United States

Site Status

#018

Green Valley, Arizona, United States

Site Status

#110

Mesa, Arizona, United States

Site Status

#105

Phoenix, Arizona, United States

Site Status

#188

Tucson, Arizona, United States

Site Status

#107

Jonesboro, Arkansas, United States

Site Status

#019

North Little Rock, Arkansas, United States

Site Status

#140

Searcy, Arkansas, United States

Site Status

#059

Anaheim, California, United States

Site Status

#179

Anaheim, California, United States

Site Status

#032

Chino, California, United States

Site Status

#154

Cypress, California, United States

Site Status

#004

Garden Grove, California, United States

Site Status

#144

Long Beach, California, United States

Site Status

#043

Los Angeles, California, United States

Site Status

#139

Los Angeles, California, United States

Site Status

#096

Oxnard, California, United States

Site Status

#091

Pacific Palisades, California, United States

Site Status

#114

Pasadena, California, United States

Site Status

#111

Pico Rivera, California, United States

Site Status

#097

Pomona, California, United States

Site Status

#068

Sacramento, California, United States

Site Status

#035

San Diego, California, United States

Site Status

#054

San Diego, California, United States

Site Status

#042

Torrance, California, United States

Site Status

#197

Bridgeport, Connecticut, United States

Site Status

#022

Boca Raton, Florida, United States

Site Status

#152

Boynton Beach, Florida, United States

Site Status

#060

Coral Gables, Florida, United States

Site Status

#007

Delray Beach, Florida, United States

Site Status

#086

Edgewater, Florida, United States

Site Status

#016

Fort Myers, Florida, United States

Site Status

#038

Gainesville, Florida, United States

Site Status

#014

Hialeah, Florida, United States

Site Status

#052

Hialeah, Florida, United States

Site Status

#088

Hialeah, Florida, United States

Site Status

#035

Jacksonville, Florida, United States

Site Status

#094

Kissimmee, Florida, United States

Site Status

#153

Kissimmee, Florida, United States

Site Status

#177

Lauderdale Lakes, Florida, United States

Site Status

#012

Melbourne, Florida, United States

Site Status

#034

Miami, Florida, United States

Site Status

#040

Miami, Florida, United States

Site Status

#047

Miami, Florida, United States

Site Status

#082

Miami, Florida, United States

Site Status

#166

Miami, Florida, United States

Site Status

#149

Miami Gardens, Florida, United States

Site Status

#134

Pinellas Park, Florida, United States

Site Status

#050

Port Orange, Florida, United States

Site Status

#163

Venice, Florida, United States

Site Status

#020

West Palm Beach, Florida, United States

Site Status

#814

Snellville, Georgia, United States

Site Status

#080

Honolulu, Hawaii, United States

Site Status

#063

Boise, Idaho, United States

Site Status

#835

Oak Lawn, Illinois, United States

Site Status

#804

Fishers, Indiana, United States

Site Status

#803

Franklin, Indiana, United States

Site Status

#198

Greenfield, Indiana, United States

Site Status

#195

Munci, Indiana, United States

Site Status

#168

Council Bluffs, Iowa, United States

Site Status

#827

West Des Moines, Iowa, United States

Site Status

#008

Newton, Kansas, United States

Site Status

#138

Shawnee, Kansas, United States

Site Status

#106

Wichita, Kansas, United States

Site Status

#055

Hazard, Kentucky, United States

Site Status

#823

Alexandria, Louisiana, United States

Site Status

#801

Baton Rouge, Louisiana, United States

Site Status

#048

Elkridge, Maryland, United States

Site Status

#085

Silver Spring, Maryland, United States

Site Status

#187

Worcester, Massachusetts, United States

Site Status

#811

Detroit, Michigan, United States

Site Status

#015

Bellevue, Nebraska, United States

Site Status

#170

Bellevue, Nebraska, United States

Site Status

#081

Lincoln, Nebraska, United States

Site Status

#017

Omaha, Nebraska, United States

Site Status

#041

Omaha, Nebraska, United States

Site Status

#169

Omaha, Nebraska, United States

Site Status

#112

Henderson, Nevada, United States

Site Status

#146

Henderson, Nevada, United States

Site Status

#079

Las Vegas, Nevada, United States

Site Status

#176

Las Vegas, Nevada, United States

Site Status

#171

Brooklyn, New York, United States

Site Status

#011

Endwell, New York, United States

Site Status

#164

New York, New York, United States

Site Status

#021

Harrisburg, North Carolina, United States

Site Status

#178

High Point, North Carolina, United States

Site Status

#189

Morganton, North Carolina, United States

Site Status

#030

Carlisle, Ohio, United States

Site Status

#006

Cleveland, Ohio, United States

Site Status

#182

Grove City, Ohio, United States

Site Status

#083

Wadsworth, Ohio, United States

Site Status

#167

Oklahoma City, Oklahoma, United States

Site Status

#810

Oklahoma City, Oklahoma, United States

Site Status

#071

Tulsa, Oklahoma, United States

Site Status

#045

Portland, Oregon, United States

Site Status

#024

Bridgeville, Pennsylvania, United States

Site Status

#815

Clairton, Pennsylvania, United States

Site Status

#192

Harleysville, Pennsylvania, United States

Site Status

#816

Philladelphia, Pennsylvania, United States

Site Status

#191

Pittsburgh, Pennsylvania, United States

Site Status

#828

Scottdale, Pennsylvania, United States

Site Status

#824

Uniontown, Pennsylvania, United States

Site Status

#194

Johnston, Rhode Island, United States

Site Status

#819

Clinton, South Carolina, United States

Site Status

#805

Easley, South Carolina, United States

Site Status

#160

Murrells Inlet, South Carolina, United States

Site Status

#833

Orangeburg, South Carolina, United States

Site Status

#831

Pawleys Island, South Carolina, United States

Site Status

#147

Simpsonville, South Carolina, United States

Site Status

#002

Rapid City, South Dakota, United States

Site Status

#084

Clarksville, Tennessee, United States

Site Status

#001

Amarillo, Texas, United States

Site Status

#812

Arlington, Texas, United States

Site Status

#137

Austin, Texas, United States

Site Status

#037

Beaumont, Texas, United States

Site Status

#113

Bryan, Texas, United States

Site Status

#058

Carrollton, Texas, United States

Site Status

#066

Corpus Christi, Texas, United States

Site Status

#039

Houston, Texas, United States

Site Status

#053

Houston, Texas, United States

Site Status

#132

Houston, Texas, United States

Site Status

#136

Houston, Texas, United States

Site Status

#157

Houston, Texas, United States

Site Status

#158

Katy, Texas, United States

Site Status

#003

San Antonio, Texas, United States

Site Status

#108

San Antonio, Texas, United States

Site Status

#180

San Antonio, Texas, United States

Site Status

#817

San Antonio, Texas, United States

Site Status

#818

San Antonio, Texas, United States

Site Status

#830

Sugar Land, Texas, United States

Site Status

#135

Tomball, Texas, United States

Site Status

#809

Tomball, Texas, United States

Site Status

#822

Draper, Utah, United States

Site Status

#090

Orem, Utah, United States

Site Status

#117

Salt Lake City, Utah, United States

Site Status

#832

Salt Lake City, Utah, United States

Site Status

#825

South Jordan, Utah, United States

Site Status

#133

West Jordan, Utah, United States

Site Status

#142

Alexandria, Virginia, United States

Site Status

#800

Alexandria, Virginia, United States

Site Status

#009

Richmond, Virginia, United States

Site Status

#172

Spokane, Washington, United States

Site Status

#216

Blacktown, New South Wales, Australia

Site Status

#207

Burwood, New South Wales, Australia

Site Status

#214

Carlton, New South Wales, Australia

Site Status

#208

Darlinghurst, New South Wales, Australia

Site Status

#205

Glebe, New South Wales, Australia

Site Status

#201

Maroubra, New South Wales, Australia

Site Status

#218

Neutral Bay, New South Wales, Australia

Site Status

#202

Sydney, New South Wales, Australia

Site Status

#204

Sydney, New South Wales, Australia

Site Status

#219

Biggera Waters, Queensland, Australia

Site Status

#215

Caboolture, Queensland, Australia

Site Status

#221

Deception Bay, Queensland, Australia

Site Status

#217

Jimboomba, Queensland, Australia

Site Status

#220

Nerang, Queensland, Australia

Site Status

#206

Sherwood, Queensland, Australia

Site Status

#223

Mirrabooka, Western Australia, Australia

Site Status

#222

Morley, Western Australia, Australia

Site Status

#224

Spearwood, Western Australia, Australia

Site Status

#613

Antofagasta, , Chile

Site Status

#612

Curicó, , Chile

Site Status

#606

Quillota, , Chile

Site Status

#614

Rancagua, , Chile

Site Status

#603

Santiago, , Chile

Site Status

#607

Santiago, , Chile

Site Status

#609

Santiago, , Chile

Site Status

#610

Santiago, , Chile

Site Status

#602

Talca, , Chile

Site Status

#600

Temuco, , Chile

Site Status

#601

Temuco, , Chile

Site Status

#611

Viña del Mar, , Chile

Site Status

#306

Otara, Auckland, New Zealand

Site Status

#305

Rotorua, Bay of Plenty, New Zealand

Site Status

#302

Tauranga, Bay of Plenty, New Zealand

Site Status

#301

Christchurch, Canterbury, New Zealand

Site Status

#304

Dunedin, Otago, New Zealand

Site Status

#307

Auckland, , New Zealand

Site Status

#308

Hamilton, , New Zealand

Site Status

#703

Esquina Pai Perez, Asunción, Paraguay

Site Status

#702

Florida, Asunción, Paraguay

Site Status

#707

Pai Perez, Asunción, Paraguay

Site Status

#704

Campos Cervera, Luque, Paraguay

Site Status

#505

Arequipa, , Peru

Site Status

#511

Callao, , Peru

Site Status

#506

Cusco, , Peru

Site Status

#513

Ica, , Peru

Site Status

#500

Lima, , Peru

Site Status

#501

Lima, , Peru

Site Status

#502

Lima, , Peru

Site Status

#504

Lima, , Peru

Site Status

#508

Lima, , Peru

Site Status

#509

Lima, , Peru

Site Status

#510

Lima, , Peru

Site Status

#512

Lima, , Peru

Site Status

#515

Lima, , Peru

Site Status

#516

Lima, , Peru

Site Status

#517

Lima, , Peru

Site Status

#514

Piura, , Peru

Site Status

#507

Trujillo, , Peru

Site Status

#421

Benoni, , South Africa

Site Status

#402

Cape Town, , South Africa

Site Status

#405

Durban, , South Africa

Site Status

#406

Durban, , South Africa

Site Status

#408

Durban, , South Africa

Site Status

#412

Durban, , South Africa

Site Status

#414

Durban, , South Africa

Site Status

#404

Johannesburg, , South Africa

Site Status

#422

Kempton Park, , South Africa

Site Status

#411

Kraaifontein, , South Africa

Site Status

#410

Krugersdorp, , South Africa

Site Status

#407

Port Elizabeth, , South Africa

Site Status

#409

Pretoria, , South Africa

Site Status

#413

Pretoria, , South Africa

Site Status

#415

Pretoria, , South Africa

Site Status

#418

Pretoria, , South Africa

Site Status

#419

Pretoria, , South Africa

Site Status

#420

Pretoria, , South Africa

Site Status

#423

Pretoria, , South Africa

Site Status

#417

Sandton, , South Africa

Site Status

#416

Somerset West, , South Africa

Site Status

#401

Soweto, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Chile New Zealand Paraguay Peru South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Hayden FG, Lenk RP, Epstein C, Kang LL. Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza. J Infect Dis. 2024 Aug 16;230(2):e395-e404. doi: 10.1093/infdis/jiad409.

Reference Type DERIVED
PMID: 37739792 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

T705aUS204

Identifier Type: -

Identifier Source: org_study_id